Publicacions en col·laboració amb investigadors/es de Instituto de Investigación Sanitaria de Navarra (8)

2023

  1. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

  2. Reply to I.V. Kostopoulos et al

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 3, pp. 710-711

2022

  1. Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 8

2021

  1. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

2020

  1. Characterization of freshly isolated mesenchymal stromal cells from healthy and multiple myeloma bone marrow: Transcriptional modulation of the microenvironment.

    Haematologica, Vol. 105, Núm. 5

2019

  1. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity

    Haematologica

2015

  1. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

    Leukemia